Drugmaker Cipla clocked a 4 per cent growth in profit after tax at ₹1,351 crore for the second ended quarter ended September 30, 2025.

“In Q2FY26, we delivered our highest-ever quarterly revenue of INR 7,589 crore, with a robust EBITDA margin of 25 per cent. What makes this performance commendable is the breadth and balance of our growth, driven by contributions across all our focused markets,” said Umang Vohra, Cipla’s outgoing MD and Global CEO.

Pointing to the launch of Yurpeak (Tirzepatide), Cipla’s brand of Eli Lilly’s weightloss and diabetes drug Mounjaro announced just days ago, Vohra said “we mark a pivotal step into obesity care through our strategic partnership with Eli Lilly”.

Commenting on the financial performance for the quarter, he said: “Our One-India business grew 7 per

See Full Page